[{"id":"e5b1a6c3-e729-4a52-a992-a915116be9cb","acronym":"CisCon","url":"https://clinicaltrials.gov/study/NCT05406674","created_at":"2022-06-06T12:57:31.984Z","updated_at":"2024-07-02T16:35:34.440Z","phase":"Phase 2","brief_title":"Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer","source_id_and_acronym":"NCT05406674 - CisCon","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" KRT7 • KRT20 • PAX8","pipe":"","alterations":" ","tags":["KRT7 • KRT20 • PAX8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/15/2022","start_date":" 06/15/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-06"},{"id":"03185639-6494-4888-9d7d-ca64f80d0912","acronym":"BEACON","url":"https://clinicaltrials.gov/study/NCT03363867","created_at":"2021-01-18T16:36:09.574Z","updated_at":"2024-07-02T16:35:40.759Z","phase":"Phase 2","brief_title":"BEACON - ABC in Recurrent Platinum Resistant HGSOC","source_id_and_acronym":"NCT03363867 - BEACON","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" WT1 • MUC16 • PAX8","pipe":" | ","alterations":" WT1 positive","tags":["WT1 • MUC16 • PAX8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-08-07"},{"id":"160de920-0123-4feb-9f61-df7a1bc389da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03765333","created_at":"2021-01-18T18:37:59.192Z","updated_at":"2024-07-02T16:36:06.197Z","phase":"","brief_title":"GETNE Registration of Thyroid Cancer","source_id_and_acronym":"NCT03765333","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" BRAF • TP53 • RET • PTEN • RAS • PAX8 • PI3K","pipe":" | ","alterations":" TP53 mutation • BRAF mutation • PTEN mutation • RAS mutation • RET mutation","tags":["BRAF • TP53 • RET • PTEN • RAS • PAX8 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRAF mutation • PTEN mutation • RAS mutation • RET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/28/2019","start_date":" 05/28/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-08-03"},{"id":"95e2fcd2-7528-4f46-8f55-3dec31eeebbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01655719","created_at":"2021-01-18T07:08:24.420Z","updated_at":"2024-07-02T16:37:16.829Z","phase":"Phase 2","brief_title":"Pioglitazone in Thyroid Cancers","source_id_and_acronym":"NCT01655719","lead_sponsor":"University of Michigan","biomarkers":" PPARG • PAX8 • TG","pipe":"","alterations":" ","tags":["PPARG • PAX8 • TG"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 03/31/2017","primary_completion_date":" 03/31/2017","study_txt":" Completion: 03/31/2017","study_completion_date":" 03/31/2017","last_update_posted":"2017-10-26"}]